Former Lotte Biologics founding CEO tapped to transform Osong plant into a global production hub.
With overseas sales at 2.9% and Osong plant utilization at 12.7%, export growth remains the key to future performance.
HLB Pep, a company specializing in peptide active pharmaceutical ingredients (API), is accelerating its push into international markets by recruiting a veteran expert in global biopharmaceutical production. The company aims to shift its business structure from a domestic-focused model to a global API supply chain, leveraging its production facilities to drive earnings growth.
HLB Pep announced on the 17th that it has appointed Lee Won-jik, former CEO of Lotte Biologics, as its new president. President Lee is expected to lead the company's global expansion, with a primary focus on upgrading production and quality systems at the Osong and Jangseong plants and securing international clients.
President Lee is a seasoned expert in global biopharmaceutical manufacturing and contract development and manufacturing organization (CDMO) operations. He previously managed quality operations at Bristol Myers Squibb (BMS) in the U.S. and was a founding member of Samsung Biologics, where he spent approximately 11 years building drug substance production organizations and leading finished product operations.
In 2022, he was appointed as the inaugural CEO of Lotte Biologics, where he spearheaded the acquisition of BMS's Syracuse plant in the U.S., laying the foundation for the company's global manufacturing business.
Overseas Sales at 2.9%: Global Client Acquisition is Critical
The core objective of this appointment is to translate HLB Pep's existing peptide manufacturing capabilities into increased overseas revenue.
While HLB Pep possesses advanced technology for producing research-grade peptides and pharmaceutical raw materials, the vast majority of its revenue is generated domestically. As of the third quarter of 2026, cumulative revenue reached approximately 4.2 billion KRW, a 20.3% increase year-on-year, yet the share of overseas sales remained at a mere 2.9%.
Improving the utilization of production facilities is another critical task. During the same period, the utilization rate of the Osong GMP plant stood at 12.71%, significantly lower than the 61.92% recorded at the Jangseong GMP plant. Transforming the Osong facility into a global API production hub will require securing international clients and ensuring a stable increase in production volume.
Profitability also requires attention. HLB Pep's cumulative operating loss for the third quarter of this year was approximately 4.3 billion KRW, widening from the 4.1 billion KRW loss recorded in the same period last year. As losses persist despite revenue growth, securing new orders and improving production efficiency have become urgent priorities.
To this end, the company is investing in expanding production equipment and strengthening quality competitiveness at the Osong plant. It plans to invest a total of 4.15 billion KRW in production equipment, including continuous purification liquid chromatography systems, by February 2027.
Expansion into Obesity Drug Ingredients: Targeting Supply by 2028
The company is also pursuing new API business opportunities. During a corporate briefing in October, HLB Pep identified semaglutide and terzepatide—key components for obesity treatments—as its next-generation business items.
The company plans to develop the necessary manufacturing processes to supply these ingredients to generic pharmaceutical companies in countries where patents have expired, with a target to begin supply after 2028.
However, expanding exports will require meeting patent and regulatory requirements in each target country, as well as securing quality validation and commercial supply contracts from global pharmaceutical firms.
Leveraging President Lee's extensive experience in global production and business operations, HLB Pep plans to establish a quality management system that complies with international regulatory standards, such as those of the U.S. Food and Drug Administration (FDA), and expand partnerships with global pharmaceutical companies.
"HLB Pep possesses the technical expertise and production capabilities built in the peptide API sector," said Lee Won-jik, the new president of HLB Pep. "I will solidify our quality systems to meet global regulatory standards and build trust with international clients to establish HLB Pep as a key API supply partner for global pharmaceutical companies."







